证券代码：688136 证券简称：科兴制药 公告编号：2025-089 科兴生物制药股份有限公司 自愿披露关于 GB18 注射液 I 期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科 兴药业有限公司（以下简称"深圳科兴"）研发的"GB18注射液"I期临床研究 成功完成首例受试者入组给药。 公司子公司深圳科兴于 2025 年 5 月获得国家药品监督管理局（以下简称"国 家药监局"）签发的《药物临床试验批准通知书》（受理号：CXSL2500226）， 国家药监局同意深圳科兴 GB18 注射液按照提交的方案开展肿瘤恶病质的临床 试验。 1 公司 GB18 注射液正在开展随机、双盲、安慰剂对照的Ⅰ期临床研究，旨在 评估 GB18 注射液在健康参与者中单次皮下给药和肿瘤恶病质患者中多次皮下 给药的安全性、耐受性、药代动力学、药效学特征以及在肿瘤恶病质患者中初步 有效性，于近日成功完成首例受试者入组给药。 此外，公司 GB18 注射液 ...

第三季度财务报表是否经审计 □是 √否 一、主要财务数据 科兴生物制药股份有限公司 2025 年第三季度报告 证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 447,174,374.72 | 60.65 | 1,147, ...

科兴制药公告，全资子公司深圳科兴药业有限公司研发的"GB18注射液"I期临床研究成功完成首例受试 者入组给药。 ...

Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, particularly through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau [1] Group 1: International Expansion - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau, aiming to leverage regional presence for brand expansion [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2: Market Monitoring and Production - The company is closely monitoring disease dynamics to ensure effective production and sales of its pharmaceuticals [1]

Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, specifically through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau, which aims to enhance its brand presence overseas and support its international expansion efforts [1] Group 1 - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau [1] - This collaboration is intended to create a brand radiating effect in international markets [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2 - The company is closely monitoring disease dynamics and is committed to effective drug production and sales [1]

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline recently, despite a significant increase in its price year-to-date, indicating potential volatility in the market [1]. Financial Performance - As of June 30, Kexing Pharmaceutical reported a revenue of 700 million yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.34 million yuan, showing a substantial increase of 576.45% [2]. - Cumulatively, Kexing Pharmaceutical has distributed dividends amounting to 51.54 million yuan since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2]. - The top ten circulating shareholders include notable funds such as E Fund Healthcare Industry Mixed A and others, with significant increases in holdings for some [3].

Core Insights - The successful shipment of the first batch of Bevacizumab biosimilar to Colombia marks a significant milestone for the company in deepening its presence in the Latin American market [1] Group 1: Overseas Commercialization Strategy - The company has been actively advancing the overseas registration of its collaborative products, receiving industry acclaim for its "multi-country registration" commercial efficiency [2] - The innovative "global selection + global coverage" outbound platform model has led to partnerships with several well-known pharmaceutical companies, securing over twenty key products for overseas commercialization across diverse therapeutic areas [2] - Colombia, as the fourth largest pharmaceutical market in Latin America, has seen a notable increase in the export of Chinese pharmaceutical products, with a 10.4% year-on-year growth in the first quarter of 2025 [2] Group 2: Regulatory and Market Entry - The Colombian pharmaceutical market is a key focus for the company, with the local regulatory body INVIMA's standards closely aligned with international authorities like the FDA and EMA, indicating a high level of market entry rigor [2] - The INVIMA certification is expected to facilitate the introduction of Bevacizumab in other Latin American markets, enhancing the company's overall market penetration strategy [2] Group 3: Collaborative Efforts and Future Plans - The successful commercialization of Bevacizumab overseas is attributed to the deep collaboration between the company and its partner, which ensures stringent production compliance and high product quality [3] - The company plans to continue advancing the registration of Bevacizumab in Latin America and other key markets, while also enhancing its local operational capabilities for other products [3] - The ongoing efforts aim to expand the company's international footprint and provide hope for more patients through access to essential medications [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on October 17, 2025, at the Innovation Technology Building in Shenzhen [5] - The meeting was convened by the board of directors and chaired by Chairman Deng Xueqin, utilizing a combination of on-site and online voting methods [2][3] Attendance - All 8 current directors attended the meeting, along with the board secretary Wang Xiaoqin and other senior management personnel [3] Resolutions Passed - The following key resolutions were approved during the meeting: - Proposal for the company to issue H-shares and list on the Hong Kong Stock Exchange [4] - Various aspects of the H-share issuance, including types and par value, issuance timing, method, scale, pricing, and target investors, were all approved [6][7] - The proposal to convert the company into an overseas fundraising joint-stock company was approved [7] - The fundraising usage plan for the H-share issuance was approved [7] - Authorization for the board of directors and its authorized personnel to handle matters related to the H-share issuance was approved [7] - Profit distribution plan prior to the H-share issuance was approved [7] - Amendments to the company's articles of association and related rules post-H-share issuance were approved [8] Legal Verification - The meeting was witnessed by Beijing Jiayuan Law Firm, confirming that the convening, procedures, and voting were in compliance with relevant laws and regulations [10]

证券代码：688136 证券简称：科兴制药 公告编号：2025-088 科兴生物制药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 17 日 （二） 股东会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创益 科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 80 | | --- | --- | | 普通股股东人数 | 80 | | 2、出席会议的股东所持有的表决权数量 | 112,192,882 | | 普通股股东所持有表决权数量 | 112,192,882 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 ...